The segmentation of the Avascular Necrosis Market Segment is strongly driven by the specific anatomical site affected, as the treatment strategy varies significantly based on the joint involved. The largest and most revenue-intensive Avascular Necrosis Market Segment is Hip (Femoral Head) AVN. This segment dominates due to the frequency of the condition in the femoral head and the high cost of the resulting treatment, which is predominantly Total Hip Arthroplasty (THA), requiring high-value, premium-priced orthopedic implants. The clinical urgency to address hip AVN, which significantly impairs mobility, ensures this segment's financial dominance.

A second, distinct Avascular Necrosis Market Segment involves Knee (Femoral Condyle) AVN. While less common than hip involvement, knee AVN is typically treated with procedures ranging from conservative measures (rest, medications) and osteotomy (bone realignment) to unicompartmental or total knee replacement. The treatment path in this segment is more varied, supporting a broader market for hardware, bracing, and bone grafts. The third major Avascular Necrosis Market Segment involves Smaller Joints and Bones, such as the shoulder (humeral head), wrist (scaphoid, lunate), and ankle (talus). These areas are often treated with conservative methods, specialized bone grafts, or limited joint fusions. While the revenue from smaller joint replacements or fusions is less than that of the hip, the specialization required for the associated surgical instruments and grafting materials creates a valuable niche market. Manufacturers must offer a diversified portfolio of products tailored to the unique biomechanical challenges and surgical requirements of each anatomical Avascular Necrosis Market Segment.